NO20005887D0 - Forbindelser med IgE-påvirkende egenskaper - Google Patents

Forbindelser med IgE-påvirkende egenskaper

Info

Publication number
NO20005887D0
NO20005887D0 NO20005887A NO20005887A NO20005887D0 NO 20005887 D0 NO20005887 D0 NO 20005887D0 NO 20005887 A NO20005887 A NO 20005887A NO 20005887 A NO20005887 A NO 20005887A NO 20005887 D0 NO20005887 D0 NO 20005887D0
Authority
NO
Norway
Prior art keywords
ige
compounds
affecting properties
affecting
properties
Prior art date
Application number
NO20005887A
Other languages
English (en)
Other versions
NO20005887L (no
Inventor
Jagadish Sircar
Mark L Richards
Michael G Campbell
Michael W Major
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22198947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20005887(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Publication of NO20005887D0 publication Critical patent/NO20005887D0/no
Publication of NO20005887L publication Critical patent/NO20005887L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Amplifiers (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
NO20005887A 1998-05-22 2000-11-21 Forbindelser med IgE-påvirkende egenskaper NO20005887L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8649498P 1998-05-22 1998-05-22
PCT/US1999/011363 WO1999061013A2 (en) 1998-05-22 1999-05-21 COMPOUNDS HAVING IgE AFFECTING PROPERTIES

Publications (2)

Publication Number Publication Date
NO20005887D0 true NO20005887D0 (no) 2000-11-21
NO20005887L NO20005887L (no) 2001-01-19

Family

ID=22198947

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20005889A NO20005889L (no) 1998-05-22 2000-11-21 Benzimidazolderivater som ned-regulatorer av IgE
NO20005887A NO20005887L (no) 1998-05-22 2000-11-21 Forbindelser med IgE-påvirkende egenskaper
NO20005888A NO20005888L (no) 1998-05-22 2000-11-21 Benzimidazolderivater som mudulatorer av IgE

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20005889A NO20005889L (no) 1998-05-22 2000-11-21 Benzimidazolderivater som ned-regulatorer av IgE

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20005888A NO20005888L (no) 1998-05-22 2000-11-21 Benzimidazolderivater som mudulatorer av IgE

Country Status (22)

Country Link
US (2) US6271390B1 (no)
EP (3) EP1079830A1 (no)
JP (3) JP2002516277A (no)
KR (1) KR100591652B1 (no)
CN (4) CN1721411A (no)
AT (1) ATE292465T1 (no)
AU (3) AU4197899A (no)
BR (3) BR9910642A (no)
CA (3) CA2332989A1 (no)
CZ (2) CZ20004350A3 (no)
DE (1) DE69924607T2 (no)
ES (1) ES2241285T3 (no)
HU (3) HUP0102128A3 (no)
IL (3) IL139826A0 (no)
MX (3) MXPA00011467A (no)
NO (3) NO20005889L (no)
NZ (2) NZ508416A (no)
PL (3) PL345219A1 (no)
RU (2) RU2236221C2 (no)
UA (2) UA67775C2 (no)
WO (3) WO1999061013A2 (no)
ZA (3) ZA200007754B (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911462B2 (en) 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
CA2332989A1 (en) * 1998-05-22 1999-12-02 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of ige
US6919366B2 (en) 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
CN1325380A (zh) * 1998-09-11 2001-12-05 味之素株式会社 苯衍生物和它们的药物用途
US6270746B1 (en) * 1999-02-17 2001-08-07 David H. Katz Assay for the identification of IgE antibody suppressors
AU782353B2 (en) * 1999-03-26 2005-07-21 Euro-Celtique S.A. Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
EP1193255A4 (en) * 1999-07-01 2002-08-07 Ajinomoto Kk HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS IN MEDICINE
EP1211240A4 (en) 1999-09-01 2003-02-12 Ajinomoto Kk BISCYCLOPROPANOCARBOXYLIC ACID AMIDE COMPOUNDS AND MEDICINAL USE THEREOF
US6759425B2 (en) 1999-10-21 2004-07-06 Avanir Pharmaceuticals Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
DK1368028T3 (da) * 2001-03-12 2007-12-27 Avanir Pharmaceuticals Benzimidazolforbindelser til IgE-modulering og inhibering af cellulær profi-ferering
PL366799A1 (en) * 2001-07-27 2005-02-07 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US7271261B2 (en) 2001-10-19 2007-09-18 Ortho-Mcneil Pharmaceutical, Inc. Substituted benzimidazoles and imidazo-[4,5]-pyridines
US20080081788A1 (en) * 2002-01-14 2008-04-03 Lipps Binie V Diagnosis and treatment for immunoglobulin E (IgE) implicated disorders
US20030157555A1 (en) * 2002-01-14 2003-08-21 Lipps Binie V. Diagnosis and treatment for immunoglobulin E ( IgE) implicated disorders
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
WO2003101927A1 (en) 2002-05-31 2003-12-11 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
EP1388535A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
US7425620B2 (en) 2002-08-14 2008-09-16 Scott Koenig FcγRIIB-specific antibodies and methods of use thereof
WO2004024655A2 (en) 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
US20050239844A1 (en) * 2002-11-02 2005-10-27 Kyung-Lim Lee Composition fo preventing secretion of immunoglobulin e-dependent histamine releasing factor
GB2397301A (en) * 2003-01-14 2004-07-21 Novo Pharmaceuticals Ltd De Substituted 1,3,5-triazine derivatives
EP1613313B1 (en) 2003-04-17 2007-06-06 Janssen Pharmaceutica N.V. 2-phenyl-benzimidazol and 2-phenyl-imidazo-4,5]-pyridine derivatives as checkpoint kinase cds1 (chk2) inhibitors for the treatment of cancer
EP1651198A2 (en) * 2003-08-08 2006-05-03 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
US7582770B2 (en) 2004-02-20 2009-09-01 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
NZ551589A (en) * 2004-05-12 2009-10-30 Proteotech Inc Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies
WO2006004791A1 (en) 2004-06-30 2006-01-12 Janssen Pharmaceutica, N.V. Aryl-substituted benzimidazole and imidazopyridine ethers as anti-cancer agents
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
ATE533485T1 (de) † 2005-10-31 2011-12-15 Merck Sharp & Dohme Cetp-inhibitoren
EP1790345A1 (en) * 2005-11-02 2007-05-30 Esbatech AG Triazin beta-secretase inhibitors
CA2635760C (en) * 2005-12-28 2014-07-15 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2029173B1 (en) 2006-06-26 2016-07-20 MacroGenics, Inc. Fc riib-specific antibodies and methods of use thereof
US20100112606A1 (en) * 2008-10-17 2010-05-06 Michael Armstrong Measurement and analysis of leukotrienes
CN102264737A (zh) 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
CN102245604A (zh) 2008-12-23 2011-11-16 雅培制药有限公司 抗病毒化合物
EP2419404B1 (en) 2009-04-15 2015-11-04 AbbVie Inc. Anti-viral compounds
NZ591973A (en) 2009-06-11 2013-03-28 Abbott Lab Anti-viral compounds to treat hcv infection
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8420655B2 (en) 2009-12-04 2013-04-16 Boehringer Ingelheim International Gmbh Benzimidazole inhibitors of leukotriene production
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
BR112013001217B1 (pt) 2010-07-20 2019-11-19 Vestaron Corp composto, composição inseticida contendo o mesmo, e, método para controlar insetos
JP5928958B2 (ja) 2010-10-29 2016-06-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成のベンゾイミダゾールインヒビター
WO2012061169A1 (en) 2010-11-01 2012-05-10 Boehringer Ingelheim International Gmbh Benzimidazole inhibitors of leukotriene production
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
US11548867B2 (en) 2017-07-19 2023-01-10 Idea Ya Biosciences, Inc. Amido compounds as AhR modulators
WO2020061086A2 (en) * 2018-09-18 2020-03-26 Terns, Inc. Compounds for treating certain leukemias
CN110054558B (zh) * 2019-05-16 2022-03-25 海门瑞一医药科技有限公司 一种1-三氟甲基环丙烷-1-甲酸的制备方法
CN112441983B (zh) * 2019-08-29 2023-09-15 山东福长药业有限公司 一种基于苯并咪唑取代的硝基苯的化合物及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3017610A (en) * 1957-03-15 1962-01-16 Curtiss Wright Corp Electronic data file processor
US4939133A (en) * 1985-10-01 1990-07-03 Warner-Lambert Company N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade
LU86258A1 (fr) 1986-01-21 1987-09-03 Rech Dermatologiques C I R D S Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
US4744026A (en) * 1986-04-11 1988-05-10 American Telephone And Telegraph Company, At&T Bell Laboratories Methods and apparatus for efficient resource allocation
IT1232252B (it) * 1989-02-22 1992-01-28 Rotta Research Lab Derivati della n fenil benzamide ad attivita' antiulcera ed antiallerica e procedimento per la loro preparazione
DE59010069D1 (de) * 1989-11-21 1996-02-29 Bayer Ag Cumarinderivate, Verfahren zu ihrer Herstellung, ihre Verwendung und Thiazolyl-essigsäurederivate als Zwischenprodukte
DK0469477T3 (da) * 1990-08-02 1995-12-27 Hoffmann La Roche Antiallergisk kombination
IE71647B1 (en) * 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
AU670949B2 (en) 1992-06-15 1996-08-08 Celltech Limited Trisubstituted phenyl derivatives as selective phosphodiesterase IV inhibitors
US5521813A (en) * 1993-01-15 1996-05-28 Strategic Weather Services System and method for the advanced prediction of weather impact on managerial planning applications
US5496826A (en) 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
US5821258A (en) 1994-12-27 1998-10-13 Mitsui Chemicals, Inc. Phenylbenzimidazole derivatives
AU4988997A (en) * 1996-10-23 1998-05-15 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
US6988076B2 (en) * 1997-05-21 2006-01-17 Khimetrics, Inc. Strategic planning and optimization system
CA2332989A1 (en) * 1998-05-22 1999-12-02 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of ige
US6910017B1 (en) * 1999-03-05 2005-06-21 Profitlogic, Inc. Inventory and price decision support
US6405175B1 (en) * 1999-07-27 2002-06-11 David Way Ng Shopping scouts web site for rewarding customer referrals on product and price information with rewards scaled by the number of shoppers using the information
US6546387B1 (en) * 1999-11-15 2003-04-08 Transcom Software Inc. Computer network information management system and method using intelligent software agents
US20020042739A1 (en) * 2000-03-13 2002-04-11 Kannan Srinivasan Method and system for creating and administering internet marketing promotions
US20020023001A1 (en) * 2000-07-11 2002-02-21 Mcfarlin James A. Method and apparatus for online creation and sale of custom local store marketing materials
US7072848B2 (en) * 2000-11-15 2006-07-04 Manugistics, Inc. Promotion pricing system and method
US20020198794A1 (en) * 2001-06-21 2002-12-26 Williams Edward P. Inventory management system for determining suggested part stocking levels for a vehicle dealer

Also Published As

Publication number Publication date
US20020010343A1 (en) 2002-01-24
NZ508416A (en) 2004-01-30
EP1077700B1 (en) 2005-04-06
AU4197899A (en) 1999-12-13
BR9910640A (pt) 2001-10-30
US6271390B1 (en) 2001-08-07
BR9910641A (pt) 2001-10-02
ZA200007752B (en) 2001-12-05
AU4312099A (en) 1999-12-13
HUP0101894A2 (hu) 2002-02-28
AU754943B2 (en) 2002-11-28
RU2236221C2 (ru) 2004-09-20
NO20005888L (no) 2001-01-22
RU2236220C2 (ru) 2004-09-20
ZA200007753B (en) 2001-07-18
CA2332989A1 (en) 1999-12-02
UA67774C2 (uk) 2004-07-15
NO20005889L (no) 2001-01-22
US6451829B2 (en) 2002-09-17
UA67775C2 (uk) 2004-07-15
WO1999061020A1 (en) 1999-12-02
CN1219510C (zh) 2005-09-21
CA2332985A1 (en) 1999-12-02
CN1311675A (zh) 2001-09-05
NO20005888D0 (no) 2000-11-21
HUP0102550A2 (hu) 2001-10-28
AU4094299A (en) 1999-12-13
BR9910642A (pt) 2001-10-09
ZA200007754B (en) 2001-08-16
JP2002516274A (ja) 2002-06-04
DE69924607T2 (de) 2006-02-02
EP1077695A2 (en) 2001-02-28
DE69924607D1 (de) 2005-05-12
WO1999061013A3 (en) 2000-04-06
MXPA00011422A (es) 2002-12-13
MXPA00011470A (es) 2002-10-17
HUP0102128A3 (en) 2002-05-28
PL345560A1 (en) 2001-12-17
CN1721411A (zh) 2006-01-18
EP1079830A1 (en) 2001-03-07
PL345952A1 (en) 2002-01-14
WO1999061013A2 (en) 1999-12-02
KR100591652B1 (ko) 2006-06-26
CN1311679A (zh) 2001-09-05
WO1999061019A1 (en) 1999-12-02
KR20010030179A (ko) 2001-04-16
AU754562B2 (en) 2002-11-21
HUP0102128A2 (hu) 2002-03-28
NO20005887L (no) 2001-01-19
HUP0102550A3 (en) 2002-11-28
IL139828A0 (en) 2002-02-10
JP2002516276A (ja) 2002-06-04
IL139826A0 (en) 2002-02-10
CZ20004351A3 (cs) 2001-10-17
CN1317965A (zh) 2001-10-17
CA2332999A1 (en) 1999-12-02
EP1077700A1 (en) 2001-02-28
HUP0101894A3 (en) 2002-07-29
CZ20004350A3 (cs) 2002-02-13
NZ508413A (en) 2003-08-29
NO20005889D0 (no) 2000-11-21
MXPA00011467A (es) 2002-10-17
ES2241285T3 (es) 2005-10-16
ATE292465T1 (de) 2005-04-15
IL139827A0 (en) 2002-02-10
JP2002516277A (ja) 2002-06-04
PL345219A1 (en) 2001-12-03

Similar Documents

Publication Publication Date Title
NO20005887L (no) Forbindelser med IgE-påvirkende egenskaper
MXJL03000027A (es) Compuestos de benzimidazol para modular la ige e inhibir la proliferacion celular.
BR0314235A (pt) Compostos de fenil-aza-benzimidazol para modulação de ige e inibição da proliferação celular
ATE389649T1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
DE60222671D1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
ES2248356T3 (es) Compuestos para tratar la enfermedad de alzheimer.
DE60216122D1 (de) Cysteinprotease-hemmer mit 2-cyano-4-amino-pyrimidinstruktur und cathepsin-k-hemmender wirkung zur behandlung von entzündungen und anderen erkrankungen
DE60223715D1 (de) Glyt1 transporter inhibitoren und deren anwendung in der behandlung von neurologischen und neuropsychiatischen krankheiten
BR0107691A (pt) Sapogeninas substituìdas e seu uso
WO2004024896A3 (en) Phenyl-indole compounds
ATE338557T1 (de) Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks
TW200503695A (en) Imidazole derivatives for treatment of allergic and hyperproliferative disorders
SE0302304D0 (sv) Novel compounds
ATE375152T1 (de) Behandlung von gastrointestinalen erkrankungen mit n-2,3,3-tetramethylbicyclo[2.2.1]heptan-2- amine
CY1106740T1 (el) Παραλλαγες του μειζονος αλλεργιογονου par j 2 του φυτου περδικακι
ATE295724T1 (de) Der duale inhibitor der cholesterylester und wachsester synthese avasimibe zur behandlung von erkrankungen des talgdrüse
NO20053247L (no) Anvendelse av levocetirizin ved behandling av vedvarende allergisk rhinitt.
ATE305041T1 (de) Kompositionen und verwendungen von cgi-69
ATE486598T1 (de) Kinase inhibitoren und deren verwendung
PT1207898E (pt) Tratamento da conjuntivite com proteinas histacalinicas
SE9901273D0 (sv) Novel compounds
PT1032415E (pt) Prevencao e/ou tratamento de condicoes alergicas
HN2003000166A (es) Amidas de acidos 2-heteroarilcarboxilicos

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application